Home / Resource Library / Polatuzumab-R-CHP vs R-CHOP in older DLBCL: Survival benefit, infectious toxicity, and cost implications in middle-income health systems
Polatuzumab-R-CHP vs R-CHOP in older DLBCL: Survival benefit, infectious toxicity, and cost implications in middle-income health systems